
Surrozen Investor Relations Material
Latest events

Q4 2022
Surrozen

Q1 2025
9 May, 2025

Q4 2024
31 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Surrozen Inc
Access all reports
Surrozen Inc., established in 2015, is a clinical-stage biotechnology firm at the forefront of developing novel therapeutics designed to selectively modulate the Wnt pathway for tissue repair and regeneration. The company's innovative approach involves the creation of targeted regenerative antibodies intended to repair a wide array of tissues and restore organ function damaged by serious diseases. Surrozen leverages advanced antibody engineering techniques and a deep understanding of Wnt pathway biology across various disease settings to design tissue-specific antibodies. These antibodies have the potential to regenerate tissue in a multitude of organs and tissues, addressing diseases such as liver, intestine, retinal, lacrimal gland, lung, cornea, pancreas, skin, and many others. The company is headquartered in South San Francisco, California, and its shares are listed on the Nasdaq.
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
SRZN
Country
🇺🇸 United States